CBRE vs IKT · P/E 43, rev $21.75B vs $215.2M cap
CBRE Group Inc Class A (CBRE) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported CBRE revenue for 2026-06-30 was $21.75B. Net income was $522.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. IKT currently screens at market cap $215.2M.
Not investment advice. Open the CBRE and IKT stock pages for the full models.
Not investment advice.